Hematology

Latest News

After adjustment for imbalances, patients in the liso-cel group had an overall response rate of 52.5%, compared with 19.2% in the standard-of-care group. | Image credit: fotogurmespb- stock.adobe.com
Liso-Cel Improves Outcomes in R/R CLL/SLL Following 2 or More Lines of Therapy

June 26th 2025

Investigators used previous trial data to compare patients receiving the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) to a real-world cohort receiving standard therapy.

Multi-hit TP53 mutations are a significant negative prognostic factor for patients with both MPN and AML, the new study found. | Image credit: MdBabul - stock.adobe.com
Multi-Hit TP53 Mutations Linked With Poor Outcomes in MPN, AML

June 20th 2025

Venetoclax showed “remarkable efficacy” in older patients, with an response rate of 91% in the octogenarian group—similar to what has been reported in younger cohorts. | Image credit: sovova - stock.adobe.com
Venetoclax Effective in Older Patients With CLL

June 20th 2025

Venetoclax duration did not have a significant impact on overall survival based on univariate analysis in patients with AML or MDS. | Image credit: Sviatlana-stock.adobe.com
Venetoclax Duration Does Not Significantly Impact OS in AML or MDS

June 18th 2025

Acute myeloid leukemia cells | Image credit: LASZLO - stock.adobe.com
Revumenib Shows Efficacy in Patients With AML and Genetic Alterations

June 12th 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

Survivors of Childhood ALL Have Risk of Neurocognitive Issues Even Before Treatment
April 14th 2018

Survivors of Childhood ALL Have Risk of Neurocognitive Issues Even Before Treatment

Laura Joszt, MA
While increased risk of neurocognitive issues, such as long-term problems with attention, is common in survivors of childhood acute lymphoblastic leukemia (ALL), the risk may actually begin before treatment, according to a study published in JAMA Oncology.
Study Revises Molecular Classification of Diffuse Large B-Cell Lymphoma
April 14th 2018

Study Revises Molecular Classification of Diffuse Large B-Cell Lymphoma

Jaime Rosenberg
Researchers have identified genetic subtypes of diffuse large B-cell lymphoma that revise the molecular classification of the disease and could provide insight into why some patients respond to treatment and others don’t.
Pediatric Sickle Cell Disease Drug Gains European Orphan Designation
April 8th 2018

Pediatric Sickle Cell Disease Drug Gains European Orphan Designation

Kelly Davio
Sancilio Pharmaceuticals announced that it has received the European Medicines Agency’s Orphan Designation for its SC411 (which it plans to market as Altemia), a proposed treatment for sickle cell disease in pediatric patients, in the European Union. The FDA granted the proposed drug a similar designation—the Rare Pediatric Disease designation—in 2017.
Dr Nina Shah Outlines New Treatments Being Studied for Multiple Myeloma
April 7th 2018

Dr Nina Shah Outlines New Treatments Being Studied for Multiple Myeloma

While there has been progress with using chimeric antigen receptor (CAR) T cells to treat multiple myeloma, these treatments aren’t ready for prime time, said Nina Shah, MD, associate professor, University of California, San Francisco, School of Medicine.
Screening for Multiple Myeloma Precursor Can Reduce Mortality and Slow Progression
April 5th 2018

Screening for Multiple Myeloma Precursor Can Reduce Mortality and Slow Progression

Laura Joszt, MA
Researchers have been trying to find a way to screen populations at high risk of developing a precursor condition to multiple myeloma in order to intervene early and reduce disease prevalence and mortality.
Site Logo
March 27th 2018

Pricing of CAR T Therapies Currently Aligns With Benefit, but Future Changes May Be Needed

Laura Joszt, MA
Despite price tags well over $350,000 for treatment, tisagenlecleucel, approved for children with B-cell acute lymphoblastic leukemia, and axicabtagene ciloleucel, approved for adults with certain B-cell subtypes of non-Hodgkin lymphoma, are considered cost effective, according to a report from the Institute for Clinical and Economic Review.
Site Logo
March 23rd 2018

In Updated Treatment Guidelines for MM, Supportive Care Still Plays a Key Role

Kelly Davio
“Even though we have all these fancy, effective drugs,” said Shaji K. Kumar, MD, “supportive care still plays an important role in multiple myeloma.”
Malignant Cells Can Predict Relapse After Treatment in Children With ALL
March 22nd 2018

Malignant Cells Can Predict Relapse After Treatment in Children With ALL

Laura Joszt, MA
Researchers have identified malignant cells that, if present, can predict whether a patient with acute lymphoblastic leukemia (ALL) will relapse after treatment.
Dr Thomas LeBlanc on Improving End-of-Life Outcomes for Patients With Blood Cancer
March 21st 2018

Dr Thomas LeBlanc on Improving End-of-Life Outcomes for Patients With Blood Cancer

Thomas LeBlanc, MD, Duke Cancer Institute, addresses the ways palliative care and hospice can improve end-of-life outcomes for patients with blood cancers.
FDA Approves Brentuximab Vedotin for Frontline Treatment of Classical Hodgkin Lymphoma
March 21st 2018

FDA Approves Brentuximab Vedotin for Frontline Treatment of Classical Hodgkin Lymphoma

Jaime Rosenberg
The FDA has approved brentuximab vedotin (Adcentris) in combination with chemotherapy for adults with previously untreated state 3 or 4 classical Hodgkin lymphoma based on results of the ECHELON-1 study.
Patients With AML Have Significantly Lower Early Mortality at NCI-Designated Cancer Centers
March 17th 2018

Patients With AML Have Significantly Lower Early Mortality at NCI-Designated Cancer Centers

Laura Joszt, MA
Patients with acute myeloid leukemia (AML) who were treated at a National Cancer Institute-designated cancer center had a 53% lower risk of early mortality, according to a study published in Cancer.
NCI Researchers Find Drug May Prevent Resistance in Toxin-Based Leukemia Treatment
March 15th 2018

NCI Researchers Find Drug May Prevent Resistance in Toxin-Based Leukemia Treatment

Samantha DiGrande
A new study recently published in Proceedings of the National Academy of Sciences has identified a possible solution for improving the efficacy of moxetumomab pasudotox, or moxe, in patients with relapsed and chemotherapy-resistant acute lymphoblastic leukemia.
Dr Thomas LeBlanc: Patients With Blood Cancer and Palliative Care
March 10th 2018

Dr Thomas LeBlanc: Patients With Blood Cancer and Palliative Care

Thomas LeBlanc, MD, Duke Cancer Institute, discusses the trends of hospice care services used among patients with blood cancer compared with patients with solid tumors.
Patients With Breast Cancer or Lymphoma Have Increased Risk of Heart Failure
March 10th 2018

Patients With Breast Cancer or Lymphoma Have Increased Risk of Heart Failure

Kaitlynn Ely
Patients who had breast cancer or lymphoma who were treated more than 3 times are more likely to develop congestive heart failure than those who did not have cancer, according to research being presented at the American College of Cardiology’s 67th Annual Scientific Session.
This Week in Managed Care: March 9, 2018
March 9th 2018

This Week in Managed Care: March 9, 2018

This week, the top managed care stories included Cigna's deal to buy Express Scripts; Seema Verma, Alex Azar, and Scott Gottlieb, MD, made the rounds at health conferences; an analysis finds FDA's accelerated approval pathway has been a success with hematology and oncology drugs.
Site Logo
March 8th 2018

Expedited Approval Is Successful for Cancer Therapies, FDA Says

Kelly Davio
Reviewing 25 years of experience with accelerated approvals (AAs) for malignant hematology and oncology drugs and biologics, FDA officials say that the AA program has demonstrated that it can be used successfully to expedite approval of safe, effective cancer therapies that balance uncertainty with the need to provide faster access to promising agents for serious and life-threatening diseases.
NIH Panel Features Experiences of Young Adults in Rare Disease Community
March 6th 2018

NIH Panel Features Experiences of Young Adults in Rare Disease Community

Kaitlynn Ely
During a discussion, 4 panelists addressed their main issues of growing up with rare diseases, including that physicians often doubted their feelings of pain and distress.
HCT Effective for Patients With Non-Hodgkin Lymphoma Regardless of Age
February 28th 2018

HCT Effective for Patients With Non-Hodgkin Lymphoma Regardless of Age

Laura Joszt, MA
New research has found that allogeneic hematopoietic stem cell transplantation is just as effective in patients with non-Hodgkin lymphoma who are age 65 and older as it is in patients between the ages of 55 and 64.
Site Logo
February 28th 2018

The Importance of Teamwork in Oncology Care Transitions

Surabhi Dangi-Garimella, PhD
Coverage of patient-centered care updates from Patient-Centered Oncology Care, November 16-17, 2017.
Blood or Marrow Transplantation Recipients Experience Higher Risks of Cognitive Impairment
February 25th 2018

Blood or Marrow Transplantation Recipients Experience Higher Risks of Cognitive Impairment

Kaitlynn Ely
Blood or marrow transplantation (BMT) can have an impact on a patient’s cognitive functioning, affecting a survivor’s ability to integrate with a group of people and return to work. In addition, BMT recipients can experience a weakened memory, a loss of attention and concentration, and difficulty learning.
ICER Report: Costs of Approved CAR T-Cell Therapies Aligned With Clinical Benefit
February 21st 2018

ICER Report: Costs of Approved CAR T-Cell Therapies Aligned With Clinical Benefit

Jaime Rosenberg
CAR T-cell therapies tisagenlecleucel (Kymriah, Novartis) and axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead) may come with hefty price tags, but the cost-effectiveness of both therapies fell below or within commonly cited thresholds of $50,000 to $150,000 per quality-adjusted life years, according to a report by the Institute for Clinical and Economic Review.
Second-Line Nilotinib May Enable Patients With CML to Achieve Treatment-Free Remission
February 21st 2018

Second-Line Nilotinib May Enable Patients With CML to Achieve Treatment-Free Remission

Laura Joszt, MA
Patients with chronic myeloid leukemia (CML) who have a sustained deep molecular response can maintain treatment-free remission for at least 48 weeks after using second-line nilotinib, according to a new study published in Annals of Internal Medicine.
Denosumab Effectively Prevented Skeletal-Related Events in Multiple Myeloma
February 16th 2018

Denosumab Effectively Prevented Skeletal-Related Events in Multiple Myeloma

Laura Joszt, MA
New research published in The Lancet Oncology found that denosumab was noninferior to zoledronic acid for time to skeletal-related events in patients with newly diagnosed multiple myeloma.
Site Logo
February 15th 2018

Pricing of Monoclonal Antibody Therapies: Higher If Used for Cancer?

Inmaculada Hernandez, PharmD, PhD Samuel W. Bott, BS Anish S. Patel, BS Collin G. Wolf, BS Alexa R. Hospodar, BS Shivani Sampathkumar, BS William H. Shrank, MD, MSHS
The annual price of monoclonal antibody therapies used in oncology and hematology is about $100,000 higher than those used in other disease states.
Study Documents Chronic Pain Associated With Sickle Cell Disease
February 14th 2018

Study Documents Chronic Pain Associated With Sickle Cell Disease

Allison Inserro
Sickle cell disease (SCD), the most common inherited blood disorder in the United States, is marked by episodes of acute pain, but there is increasing recognition that it can transition to chronic persistent SCD pain. A recent study found that the presence of pain on 3 or more days a week is independently associated with worse patient-reported pain interference and anxiety.
Adding Daratumumab to Standard-of-Care Has Clinical Benefits in Newly Diagnosed Patients With Multiple Myeloma
February 14th 2018

Adding Daratumumab to Standard-of-Care Has Clinical Benefits in Newly Diagnosed Patients With Multiple Myeloma

Laura Joszt, MA
The addition of daratumumab to standard-of-care regimens used to treat multiple myeloma, such as bortezomib, melphalan, and prednisone, decreased the risk of disease progression or death in newly diagnosed patients who were ineligible for autologous stem-cell transplantation.
New Imaging Technique Reveals Inner Structure of Red Blood Cells
February 9th 2018

New Imaging Technique Reveals Inner Structure of Red Blood Cells

Allison Inserro
Researchers have used super-resolution microscopy to unveil the geodesic mesh that supports the outer membrane of a red blood cell, in a discovery that could eventually help uncover how the malaria parasite hijacks this mesh when it invades and eventually destroys red blood cells. The work was published in the latest issue of Cell Reports.
Long-Term Follow-Up of CAR T in ALL Indicates Early Treatment Extends Survival
February 9th 2018

Long-Term Follow-Up of CAR T in ALL Indicates Early Treatment Extends Survival

Laura Joszt, MA
A long-term follow-up analyzing the toxic effects and results from a phase 1 clinical trial of adult patients with relapsed B-cell acute lymphoblastic leukemia (ALL) who were treated with CD19-specific chimeric antigen receptor (CAR) T cells found patients with low disease burden had a longer medial overall survival and a lower incidence of toxicity.
Site Logo
February 1st 2018

New Treatment Paradigm Supersedes ABVD in Advanced Hodgkin Lymphoma: The ECHELON-1 Study

Surabhi Dangi-Garimella, PhD
Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.
Site Logo
February 1st 2018

Ibrutinib Is More Effective Than Stem-Cell Transplant in Patients With Form of Chronic Leukemia

Jaime Rosenberg
Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.
<1
...
18192021222324252627>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo